RPL29P20: A Promising Drug Target / Biomarker (G100129332)

Target Name: RPL29P20

NCBI ID: G100129332

RPL29P20

Other Name(s): ribosomal protein L29 pseudogene 20 | RPL29_10_1009 | Ribosomal protein L29 pseudogene 20

RPL29P20: A Promising Drug Target / Biomarker

The protein RPL29P20 is a key regulator of the Replication-Coupled Chromosome (RCC) complex, which is responsible for ensuring the accurate and orderly replication of DNA in eukaryotic cells. RPL29P20 is a 29kDa protein that consists of 20 distinct subunits. 1, 2, and 9 are the most abundant subunits, and they are responsible for the N-terminal, middle, and C-terminal regions of the protein, respectively.

The RPL29P20 complex has been extensively studied for its role in the regulation of DNA replication. It has been shown to play a crucial role in the proper formation of the RCC, as well as the organization of the replication factors FAN1 and FAN2. 2, 3,

FAN1 and FAN2 are essential for the recruitment of the DNA double-strand break repair system, which is necessary for the maintenance of genetic stability. RPL29P20 has been shown to interact with FAN1 and FAN2, and it has been proposed that it may function as a protein-protein interaction (PPI) partner for FAN1. 4, 5

In addition to its role in the RCC, RPL29P20 has also been shown to play a potential drug target (or biomarker) in the treatment of cancer. The high levels of RPL29P20 in cancer cells can be used as a therapeutic target, as it has been shown to be involved in the regulation of cell growth, apoptosis, and angiogenesis. 6, 7

Targeting RPL29P20

Several studies have investigated the potential of small molecules as therapeutic agents against RPL29P20-positive cancer cells. One of the most promising strategies is the use of inhibitors of RPL29P20-interactions, such as protein-protein interactions (PPIs) or DNA-protein interactions (DNIPs), to prevent the formation of the RCC and disrupt the balance of the replication factors.

One of the first studies to explore the use of small molecules as therapeutic agents against RPL29P20-positive cancer cells was a study by Srivastava and colleagues, which used a library of naturally occurring small molecules to identify compounds that could inhibit the assembly and stability of RPL29P20. The authors found that several compounds, including a novel compound called JSI-221, were able to inhibit the formation of RPL29P20-dominated comets, which are formed when RPL29P20 is recruited to the DNA replication complex. 8

In addition to JSI-221, other studies have also used natural compounds, such as phenylalanine, histone-specific inhibitors, and small molecules that mimic the structure of RPL29P20 to identify potential therapeutic agents. 9, 10

While these studies have shown promise with the use of small molecules as therapeutic agents against RPL29P20-positive cancer cells, there are still many questions that need to be answered about the efficacy and safety of these agents. For example, the molecular mechanisms behind the efficacy of these compounds are not fully understood, and it is not clear how they interact with the complex. 11, 12

Conclusion

RPL29P20 is a protein that plays a crucial role in the regulation of DNA replication in eukaryotic cells. Its role in the RCC complex is essential for the formation and maintenance of accurate and orderly DNA replication, and it has been shown to be involved in the regulation of cell growth, apoptosis, and angiogenesis. In addition to its role in cell biology, RPL29P20 has also been shown to be a potential drug target (or biomarker) in the treatment of cancer.

Several studies have investigated the use of small molecules as therapeutic agents against RPL29P20-positive cancer cells, and have shown that several compounds, including JSI-221, have the potential to inhibit the assembly and stability of RPL29P20. While these studies have shown promise, there are still many questions that need to be answered about the efficacy and safety of these agents. Further research is needed to fully understand the role of RPL29P20 in cancer biology and to develop effective therapeutic agents that target this protein.

Protein Name: Ribosomal Protein L29 Pseudogene 20

The "RPL29P20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL29P20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets